Status:
COMPLETED
Modafinil in Multiple Sclerosis
Lead Sponsor:
Kessler Foundation
Collaborating Sponsors:
National Multiple Sclerosis Society
Conditions:
Multiple Sclerosis
Eligibility:
All Genders
18-60 years
Phase:
NA
Brief Summary
Deficits in new learning and memory in MS are a major complaint of patients, and have been noted to be a significant contributor to disability by numerous researchers. Modafinil is a psychostimulant m...
Detailed Description
Recent prevalence estimates of cognitive dysfunction in MS fall as high as 54-65%,21 with impairments having been documented in cognitive realms such as attention, executive control, working memory, a...
Eligibility Criteria
Inclusion
- Must understand English, diagnosis of Multiple Sclerosis
Exclusion
- Significant language comprehension deficits, age greater than 60, less than 1-month post most recent exacerbation, current treatment with corticosteroids, significant neurological history aside from MS (e.g. epilepsy, TBI), significant substance abuse history as documented by the MAST,27 significant psychiatric history (e.g. Schizophrenia, Bipolar Disorder, Major Depression), non-fluency in the English language.
Key Trial Info
Start Date :
June 1 2003
Trial Type :
INTERVENTIONAL
End Date :
September 1 2006
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00142402
Start Date
June 1 2003
End Date
September 1 2006
Last Update
September 26 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kessler Foundation
West Orange, New Jersey, United States, 07052